SREBF1 and lung adenocarcinoma: Using the clinical samples from our NSCLC cohort and GSE18842 dataset, we demonstrated that aberrant expression of SREBP-1 and SCAP was associated with disease progression and a poor prognosis in lung cancer, thus indicating their potential clinical utility as reliable diagnostic or prognostic biomarkers and as potential molecular targets for the treatment of lung adenocarcinoma.